A real-world study of treatment patterns and tolerability of second-line treatments in patients with advanced hepatocellular carcinoma
Latest Information Update: 01 Mar 2021
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium
- 11 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology